Stocktoria

NeuroPace Inc NPCE

Nasdaq · XNAS · stock · Surgical & Medical Instruments & Apparatus · website · IPO 2021-04-22

NeuroPace Inc financials (annual, from 10-K)

MetricFY2025FY2024FY2023FY2022FY2021
Revenue$100.0M$79.9M$65.4M$45.5M$45.2M
Gross profit$77.2M$59.1M$48.1M$32.5M$33.4M
R&D expense$27.9M$23.7M$20.8M$21.9M$18.2M
SG&A expense$57.1M$54.5M$51.3M$39.0M
Operating income-$16.3M-$21.7M-$27.2M-$40.8M-$23.7M
Interest expense$8.5M$7.5M$7.4M
Income tax$0
Net income-$21.5M-$27.1M-$33.0M-$47.1M-$36.1M
EPS (diluted)$-0.66$-0.93$-1.27$-1.91$-2.17
Operating cash flow-$11.0M-$17.9M-$19.7M-$36.9M-$24.6M
Free cash flow-$11.3M-$18.3M-$19.9M-$37.5M-$25.0M
Cash & equivalents$21.7M$13.4M$18.1M$6.6M$19.2M
Inventory$16.9M$13.4M$11.2M$9.7M$7.8M
Total assets$105.6M$94.6M$107.7M$114.1M$133.6M
Total liabilities$86.5M$86.6M$87.0M$79.3M$60.1M
Shareholders' equity$19.0M$8.0M$20.7M$34.8M$73.5M

Source: SEC EDGAR filings · CIK 0001528287 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.